USPTO Patent Applications - Peptides (C07K)

Novel CXC receptor ligands from GCP2

USPTO published patent application US20260092091A1 for novel polypeptide ligands of CXCR1 and/or CXCR2 derived from GCP2. The application (No. 19120219) was filed October 11, 2023, by inventors Kouvatsos, Day, Dell'Accio, and Caxaria. The invention covers polynucleotides encoding the ligands, compositions, and uses thereof.

TNF-alpha Variant Fusion Molecules

USPTO published patent application US20260092092A1 for TNF-alpha variant fusion molecules and their therapeutic uses. Inventors include Robin Allene Aglietti, Susannah Dale Barbee, Peter Michael Bowers, and Melanie Angelika Kleinschek. Application No. 19294212 was filed on 2025-08-07.

IL-18 Variant Polypeptides for Therapeutic Use

USPTO published patent application US20260092093A1 on April 2, 2026, disclosing engineered IL-18 variant polypeptides with mutations at positions G3, E6, D54, N91, C38, C68, C76, D98, S117, and C127. The variants demonstrate enhanced IL-18Rα binding and reduced IL-18BP binding compared to wild-type human IL-18 (SEQ ID NO: 1). Inventors include Min QIANG, Xi CHEN, Zhengyi WANG, Hui ZENG, Xin ZHENG, Fei ZHANG, Puwei YUAN, and Fan LIU, with original filing dated September 6, 2023.

Engineered cytokines, AI-designed polypeptides, pharmaceutical compositions

The USPTO published patent application US20260092094A1 disclosing engineered cytokines, AI-designed polypeptide structures with modulated stability, potency and developability, and pharmaceutical compositions for therapeutic use. The application, filed May 3, 2024 under Application No. 19481848, covers in silico methods using artificial neural network machine learning protocols and molecular dynamics simulations for engineering cytokines.

Interleukin-2 for Treating Autism Spectrum Disorder

USPTO published patent application US20260092095A1 by INSERM covering interleukin-2 (IL-2) for treating autism spectrum disorder (ASD). The application also extends to preventing ASD in at-risk children or through maternal administration during pregnancy. Assignee is INSERM (Institut National de la Santé et de la Recherche Médicale, France).

Antigen Receptors and Uses Thereof

USPTO published patent application US20260091060A1 by Holger Voss et al. covering recombinant antigen receptors and engineered T cells for disease treatment. The application (No. 18905085) was filed October 2, 2024 and published April 2, 2026. The invention relates to treating diseases by targeting cells expressing specific antigens using engineered T cell therapy.

Anti-GCC Antibodies and CARs for Immunotherapy

USPTO published patent application US20260091061A1 disclosing anti-GCC single domain antibodies and chimeric antigen receptors (CARs) for cancer immunotherapy. The application, filed September 28, 2023, names Xiaohu Fan, Panglian Xu, Qiuchuan Zhuang, Min Wei, Jiangjing Tang, Chenchen Zheng, and Xu Fang as inventors. This publication does not create any immediate regulatory obligations.

Fc-IL2 variant cancer therapy combination patents

USPTO published patent application US20260091062A1 by Hoffmann-La Roche Inc. covering recombinant Fc domain-IL-2 variant polypeptides combined with membrane-anchored antigen binding polypeptides for cancer treatment. The application (No. 19272092) was filed July 17, 2025, and published April 2, 2026.

Oligopeptide Inhibits Angiogenesis and Vascular Function

The USPTO published patent application US20260091078A1 covering an oligopeptide composition of 3-7 amino acids that inhibits angiogenesis and vascular function. The oligopeptide comprises defined sequence patterns with basic, small, polar, and hydrophobic amino acid residues. The application claims priority from July 7, 2020.

Saposin-A Derived Peptides with Anti-Angiogenic Activity for Tumor Treatment

The USPTO published patent application US20260091079A1 by Children's Medical Center Corporation covering Saposin-A derived polypeptides with anti-angiogenic activity. The peptides consist of 9 or fewer amino acid residues containing the active core sequence DWLP. The disclosed invention can be used to inhibit tumor growth and cancer metastasis.

Cyclic Prosaposins Peptides and Uses Thereof - Cancer Treatment

USPTO published patent application US20260091083A1 filed by Children's Medical Center Corporation for cyclic prosaposin peptides used in cancer treatment and inflammatory diseases. The application (No. 19186486) was filed on April 22, 2025, and published April 2, 2026, naming Randolph S. Watnick as inventor.

Antimicrobial peptide Halymorin variants and methods of using the same

USPTO published patent application US20260092082A1 by Antinbio, Inc. disclosing antimicrobial peptide Halymorin variants comprising amino acid sequences SEQ ID NOs: 2-12. The peptides demonstrate antimicrobial activity against Gram-negative bacteria including Campylobacter jejuni, Escherichia coli, Salmonella Typhimurium, and Klebsiella pneumoniae. Applications cover pharmaceutical compositions, food additives, cosmetics, and hygiene products, as well as methods for treating bacterial infectious diseases.

Vancomycin Derivatives with Siderophore Modification as Novel Antibiotics for Gram-Negative Bacteria

Research Triangle Institute filed USPTO patent application US20260092083A1 on April 2, 2026, disclosing novel vancomycin derivatives with siderophore modification designed as antimicrobials against Gram-negative bacteria including Acinetobacter baumannii and Escherichia coli. The application, filed March 6, 2024 under Application No. 19162234, covers compounds for treating antimicrobial-resistant infections.

Dual Target Binding Peptide Composition for Active Targeting DDS

USPTO published patent application US20260092084A1 by MESCUE-JANUSYS INC. for a dual target-binding peptide composition with hydrophilic and hydrophobic regions for active targeting drug delivery systems. The application (No. 18876803) was filed June 23, 2023 and published April 2, 2026.

Synthetic Triplex Peptide Nucleic Acid-Based Inhibitors for Cancer Therapy

The USPTO published patent application US20260092085A1 by inventors Bahal, Dhuri, and Slack disclosing novel peptide nucleic acid (PNA) oligomers designed to target microRNA-155 (miR-155) for cancer therapy. The application demonstrates in vivo efficacy in xenograft mouse models showing reduced tumor growth. The PNA oligomers form PNA/RNA/PNA triplex structures when binding target RNA sequences.

Compositions and Methods for Enhancing Wnt Signaling for Treating Cancer

USPTO published patent application US20260091038A1 on April 2, 2026, disclosing compositions and methods for enhancing Wnt signaling pathway activities for treating cancer, particularly cancers with APC gene mutations. The application covers pharmaceutical compositions containing GSK-3 inhibitors, preferably LY2090314, encapsulated in nanoparticles. Inventors are George Eng, Omer Yilmaz, and Jonathan Braverman. Application number 19294146 was filed August 7, 2025.

Biomarkers for Alzheimer's Disease Diagnosis and Treatment

USPTO published patent application US20260091025A1 by Electrophoretics Limited covering biomarker panels for Alzheimer's disease diagnosis and treatment. The application claims panels including PP1 regulatory subunit 14A, CNPase, and phosphorylated tau proteins, along with methods for diagnosing and staging neurocognitive disorders using casein kinase 1 delta inhibitors.

AAV NDP Gene Therapy for NDP-Related Diseases Including Norrie Disease and Retinopathy

USPTO published patent application US20260091131A1 by University of Massachusetts inventors disclosing AAV constructs encoding wildtype or codon-optimized NDP gene sequences for treating Norrie disease, diabetic maculopathy, retinopathy, and other NDP-related retinal diseases. The application, filed October 10, 2023, covers methods of administration including intravitreal injection for retinal neovascularization and exudation conditions.

Nanocomposite for Targeted Degradation of Pathogenic Proteins

USPTO published patent application US20260091129A1 by inventors Zhang et al. disclosing a nanocomposite system for targeted degradation of pathogenic proteins using a maleimide-PEG-PLA nanocarrier with cationic lipids and protein-targeting binding peptides. The invention enables degradation of protein aggregates through autophagy pathways, addressing limitations of PROTAC and LYTAC technologies, with applications in anti-tumor treatments and Huntington's disease.

Chimeric Antigen Receptors Binding Nectin-4 for Cancer Treatment

The USPTO published patent application US20260091114A1 by Fred Hutchinson Cancer Center disclosing Chimeric Antigen Receptors (CARs) with binding domains that target Nectin-4, derived from murine antibody M22-321b41.1. The CARs are designed for expression in immune cells to treat Nectin-4-expressing cancers including bladder, breast, ovarian, esophageal, lung, colorectal, and pancreatic cancers. Application No. 19112145 was filed September 14, 2023.

Hybrid Antibody-Peptide Molecule for Autoimmune Dermatitis

Université Toulouse III – Paul Sabatier has published patent application US20260091122A1 for a hybrid molecule combining an antibody Fc fragment with a peptide targeting autoreactive lymphocytes involved in autoimmune dermatitis. The invention covers the covalent bonding of the Fc portion to the targeting peptide and its therapeutic applications for treating autoimmune skin conditions.

PSMA-STEAP1 Dual Variable Domain Immunoglobulin DVD-Ig Molecules and Drug Conjugates

AbbVie Inc. filed US Patent Application US20260091121A2 for dual variable domain immunoglobulin (DVD-Ig) molecules binding human PSMA and STEAP1 antigens and their drug conjugates. The application (No. 18958236) was published on April 2, 2026 following filing on November 25, 2024. Competitors should monitor this IP position as it may cover cancer therapeutic constructs targeting these prostate cancer-associated antigens.

Click-to-Release Biotech Patent for Proteins and Peptides

The USPTO published patent application US20260091124A1 by inventor Michael Lukesch for a click-to-release technology involving modified peptides or proteins combined with bioorthogonally modified drugs. The application, filed September 20, 2023, and published April 2, 2026, covers bioorthogonal functional groups that enable targeted drug delivery systems for therapeutic applications.

Transgenic Non-Human Animals Producing Modified Heavy Chain-Only Antibodies

USPTO published patent application US20260090529A1 disclosing transgenic non-human animals that produce modified heavy chain-only antibodies (HCAbs). The invention involves substituting the native amino acid residue at the first position of framework region FR4 with a different residue to disrupt a surface-exposed hydrophobic patch, potentially improving antibody characteristics. Named inventors include Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, and Mike Osborn.

Universal T Cell CMV Vaccine for Influenza

USPTO published patent application US20260091102A1 for a universal T cell-based, CMV-vectored vaccine for influenza, filed by Oregon Health & Science University. The invention covers methods of generating immune responses and MHC-restricted T cells for treatment or prevention of pathogenic infections including influenza.

Amylin Receptor Agonist and GLP-1 Receptor Agonist Combination Therapy

USPTO published patent application US20260091086A1 for a combination therapy comprising amylin receptor agonists and GLP-1 receptor agonists. The application, filed on May 19, 2025, covers polypeptide combinations for therapeutic uses including weight management (A61P 3/04). Invented by Sarah WILL, the application represents a potential new approach to metabolic disorder treatment.

Micronized Antibodies in Polymeric Particles for Drug Delivery

USPTO published patent application US20260090991A1 for pharmaceutical compositions containing micronized antibodies encapsulated in polymeric particles. The inventors (Mathiowitz, Azagury, Baptista) disclose formulations designed to minimize initial burst release of antibodies. Compositions are formulated for oral, subcutaneous, or percutaneous administration for antibody-based therapies.

Metastatic cancer treatment using abscopal effect with radiotherapy

The USPTO published patent application US20260091085A1 assigned to INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising type 1 interferon combined with low-dose radiotherapy to induce systemic anticancer effects (abscopal effect) in metastatic cancer sites. The application claims a method where administering type 1 interferon with low-dose radiation to the primary tumor site produces anticancer effects at non-radiated metastatic sites.

Self-assembling peptide gel for tissue lift, repair

The USPTO published patent application US20260091159A1 by Norchi et al. disclosing compositions containing self-assembling peptides that form stable in situ gels for tissue lift, repair, and bulking applications. The formulations are designed for use during endoscopic, laparoscopic, or open surgical procedures and provide hemostatic properties with adhesion prevention for periods of days to one month.

Method for Treating Alzheimer's Disease

The USPTO published patent application US20260091109A1 disclosing a method for treating Alzheimer's disease using sequential administration of anti-amyloid beta monoclonal antibodies in increasing doses to reduce ARIA risk. The application, filed June 16, 2025, names James L. Ferrero, Leslie Lugene Williams, and Jeffrey Joseph Sevigny as inventors. This publication provides public notice of a pending patent application but creates no compliance obligations for third parties.

Anti-CCR8 antibodies and uses thereof - Vaccinex cancer treatment patents

Vaccinex, Inc. filed patent application US20260091108A1 covering anti-CCR8 antibodies and methods of treating cancer using those antibodies. The application, published April 2, 2026 with filing date November 19, 2025, names 11 inventors including Pamela M. Holland. CPC classifications indicate therapeutic antibody applications in oncology.

Anti-GPRC5D Antibody for Cancer Treatment

The USPTO has published a patent application (US20260085114A1) filed by Kyinno Biotechnology Co., Ltd. The application describes an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or fragment thereof for the treatment of tumors or cancers. It also details a bispecific antibody targeting GPRC5D and CD3.

CD3 Binding Antibodies Patent Application Inventors Listed

The USPTO has published a new patent application, US20260085115A1, related to CD3 binding antibodies. The application, filed on June 2, 2025, lists inventors Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, and Duy Pham.

Patent Application: Antibody Heavy Chain Regions Reduce Fc Gamma Receptor Binding

The USPTO has published a patent application (US20260085116A1) detailing antibody heavy chain constant regions modified to reduce binding to Fc gamma receptors. This modification, achieved through specific residue replacements or deletions in the hinge region, aims to decrease effector functions in antibodies and Fc fusion proteins.

Antibodies with chimeric constant domains reduce effector functions

The USPTO has published a patent application (US20260085117A1) detailing antibodies with chimeric constant domains designed to reduce effector functions. The application, filed on November 24, 2025, describes recombinant polypeptides and methods for their production.

Anti-CTLA-4 Antibody Conjugate Activated by Tumor Microenvironment

The USPTO has published a patent application (US20260085118A1) for a novel conjugate of an anti-CTLA-4 antibody activated by the tumor microenvironment. The application details a dual-activated conjugate designed to improve targeting efficacy, overcome drug resistance, and reduce toxicity.

Patent Application for Treating Cancer with Anti-CTLA4 Antibodies

The USPTO has published a new patent application (US20260085119A1) from ADAGENE PTE. LTD. for methods of treating cancers using anti-CTLA4 antibodies. The application details compositions and treatment methods, including combination therapies for cancers resistant to PD-1 or PD-L1 inhibitors.

Patent Application: Cancer Treatment Compositions and Methods

The USPTO has published a new patent application (US20260085120A1) for compositions and methods related to cancer treatment. The application describes binding agents, carrier proteins, and therapeutic agents, particularly for cancers expressing PD-LI or PD-L2, and lyophilized compositions.

Patent Application: Detecting Pancreatic Cancer

The USPTO has published a patent application (US20260085360A1) detailing methods for detecting pancreatic cancer. The application describes a method involving measuring CA19-9 levels alongside other markers like OPN, MIA, and CEACAM-1 in a subject's sample.

DARPIN Compositions for Treating Shiga Toxin Diseases

The USPTO has published a patent application (US20260085097A1) detailing DARPIN-containing compositions for treating Shiga toxin diseases. The application highlights the thermostability and high microbial expression yield of DARPin as advantages over antibody therapeutics.

Patent Application: Method for Acute Respiratory Distress Syndrome Treatment

The USPTO has published a new patent application (US20260085098A1) from Revolo Biotherapeutics Limited for a method to treat acute respiratory distress syndrome. The application details a treatment method involving the administration of a specific peptide molecule during or in response to a relapse to induce remission.

Process for Isolating Osteopontin and Glycomacropeptide from Whey

The USPTO has published a new patent application (US20260085099A1) detailing a process for isolating osteopontin (OPN) and glycomacropeptide (GMP) from whey. The application, filed on September 15, 2023, describes a chromatography-based method for purification.

Method for preparing biologically active complexes using polypeptides and oleic acid

Method for preparing biologically active complexes using polypeptides and oleic acid

Patent Application for Chromatographic Fractionation Method

The USPTO has published a new patent application (US20260085089A1) detailing a method and apparatus for continuous gradient elution chromatographic fractionation. The application, filed on September 12, 2023, describes a process for separating products of interest from impurities using chromatography matrices and elution solutions.

Method for Reducing Host Cell Proteins in Affinity Chromatography

The USPTO has published a patent application from Genentech, Inc. detailing a method for purifying antibodies by reducing host cell proteins using a low conductivity aqueous solution in affinity chromatography. This application, filed on December 2, 2025, describes a specific purification technique for biopharmaceutical products.

Patent Application: Peptide Binds Trop2 for Cancer Treatment

The USPTO has published a patent application (US20260085091A1) from Kyungpook National University Industry-Academic Cooperation Foundation for a peptide that selectively binds to Trop 2. The peptide is intended for targeted therapeutic agents and anticancer drugs for resistant cancers such as breast, pancreatic, and cholangiocarcinoma.

Melanocortin Receptor Ligands Patent Application

The USPTO has published a new patent application (US20260085092A1) for compounds acting as ligands for melanocortin receptors. The application details specific compounds and their potential use in treating mammals, filed by inventors Zeng Xin Dong and Jacques-Pierre Moreau.

Stapled Peptide and Use Thereof Patent Application

The USPTO has published a patent application (US20260085094A1) for a stapled peptide and its use, filed by inventors Zhixiang PAN, Haiying HE, Zhigan JIANG, and Shuhui CHEN. The application details a series of stapled peptides, specifically relating to polypeptides with sequences shown in formulas (I-1)-(I-5) and (II-6), and their pharmaceutically acceptable salts.

Patent Application for AAV Capsid Variants and Uses

The USPTO has published a new patent application (US20260085095A1) detailing adeno-associated virus (AAV) capsid variants and their uses. The application was filed on June 1, 2023, and is scheduled for publication on March 26, 2026. This represents a new disclosure in the field of gene therapy vectors.

Stabilized trimeric class I fusion proteins patent application

The USPTO has published a patent application (US20260085096A1) for stabilized trimeric class I fusion proteins. The application details specific mutations in the HR2 domain to enhance protein stability. This is a routine publication of a new patent application.